Literature DB >> 20386870

Early increase of plasma homocysteine in sepsis patients with poor outcome.

Martin Ploder1, Katharina Kurz, Andreas Spittler, Gabriele Neurauter, Erich Roth, Dietmar Fuchs.   

Abstract

Moderate hyperhomocysteinemia is a well-established coronary risk factor that develops when dietary supply with folate and/or vitamin B(12) is inadequate. Recently, stimulated peripheral blood mononuclear cells were shown to produce homocysteine. Thus, the stimulated immune system may contribute to moderate hyperhomocysteinemia during certain diseases. Because multiple trauma and sepsis are accompanied by often strong inflammatory responses, we investigated whether hyperhomocysteinemia may develop in patients. Total homocysteine and cysteine concentrations were measured in 83 plasma specimens from 18 patients (14 men, 4 women; 15 posttrauma with sepsis and 3 with sepsis alone) every third day of follow-up. Finally results were compared with concentrations of cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6, the immune activation marker neopterin and the extent of tryptophan degradation as indicated by the kynurenine-to-tryptophan ratio (kyn/trp). Compared with baseline, average total homocysteine (P < 0.05, d 4-d 10) and cysteine (P < 0.05, d 7-d 13) concentrations increased during follow-up of patients. However, only the increase of homocysteine was related to the survival status: total homocysteine was significantly higher in nonsurvivors (P < 0.05, d 4 and d 10) than in survivors, whereas cysteine concentrations increased in both subgroups. Homocysteine correlated with kyn/trp but not with neopterin concentrations. Increase of total homocysteine is common in patients after trauma with unfavorable outcome. Because all patients received standardized enteral nutrition after the end of hypodynamic shock, inconsistent vitamin supply is unlikely to be the reason for hyperhomocysteinemia in some of the patients; rather, it is associated with a stronger proinflammatory response. Certainly, the number of patients in our study is still small and results can only be regarded as preliminary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386870      PMCID: PMC2972395          DOI: 10.2119/molmed.2010.00008

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  34 in total

1.  Monocyte-derived dendritic cells release neopterin.

Authors:  Barbara Wirleitner; Daniela Reider; Susanne Ebner; Günther Böck; Bernhard Widner; Matthias Jaeger; Harald Schennach; Nikolaus Romani; Dietmar Fuchs
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

Review 2.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.

Authors:  N Rifai; P M Ridker
Journal:  Clin Chem       Date:  2001-03       Impact factor: 8.327

Review 3.  Neopterin as a marker for immune system activation.

Authors:  C Murr; B Widner; B Wirleitner; D Fuchs
Journal:  Curr Drug Metab       Date:  2002-04       Impact factor: 3.731

4.  Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.

Authors:  Pablo Avanzas; Ramon Arroyo-Espliguero; Juan Quiles; Debashis Roy; Juan Carlos Kaski
Journal:  Eur Heart J       Date:  2005-01-31       Impact factor: 29.983

Review 5.  Homocysteine, vitamins, and vascular disease prevention.

Authors:  Kilmer S McCully
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

6.  Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells.

Authors:  K Schroecksnadel; B Frick; B Wirleitner; H Schennach; D Fuchs
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

7.  The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma.

Authors:  Thorsten Hensler; Stefan Sauerland; Rolf Lefering; Manfred Nagelschmidt; Bertil Bouillon; Jonas Andermahr; Edmund A M Neugebauer
Journal:  Shock       Date:  2003-11       Impact factor: 3.454

8.  Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome.

Authors:  Juan Carlos Kaski; Luciano Consuegra-Sanchez; Daniel J Fernandez-Berges; Jose M Cruz-Fernandez; Xavier Garcia-Moll; Jaume Marrugat; Jose Mostaza; Rocio Toro-Cebada; José Ramón González-Juanatey; Gabriela Guzmán-Martínez
Journal:  Atherosclerosis       Date:  2008-03-11       Impact factor: 5.162

9.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  8 in total

1.  Folic acid prevented cognitive impairment in experimental pneumococcal meningitis.

Authors:  Tatiana Barichello; Jaqueline S Generoso; Lutiana R Simões; Amanda V Steckert; Ana Paula Moreira; Diogo Dominguini; Pâmela Ferrari; Carolina Gubert; Flávio Kapczinski; Luciano K Jornada; Lucineia G Danielski; Fabricia Petronilho; Josiane Budni; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2014-09-19       Impact factor: 3.575

2.  [Metabolomic changes of neonatal sepsis: an exploratory clinical study].

Authors:  Ping Tong; Fu-Rong Huang; Jun Xu; Zi-Qi Wu; Xing Hu; Ming Ling; Die Wang; Bu-Fei Wu; Du-Jiao Yang; Ai-Min Zhang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

3.  Neopterin as an Effect Modifier of the Cardiovascular Risk Predicted by Total Homocysteine: A Prospective 2-Cohort Study.

Authors:  Espen Ø Bjørnestad; Robert A Borsholm; Gard F T Svingen; Eva R Pedersen; Reinhard Seifert; Øivind Midttun; Per M Ueland; Grethe S Tell; Kaare H Bønaa; Ottar Nygård
Journal:  J Am Heart Assoc       Date:  2017-11-02       Impact factor: 5.501

4.  Association between plasma homocysteine concentration and the risk of all-cause death in adults with diastolic dysfunction in a community: A 13-year cohort study.

Authors:  Jing-Ling Luo; Kuo-Liong Chien; Hsiung-Ching Hsu; Ta-Chen Su; Hung-Ju Lin; Pei-Chun Chen; Ming-Fong Chen; Yuan-Teh Lee
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

Review 5.  Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease.

Authors:  Rita Moretti; Mauro Giuffré; Paola Caruso; Silvia Gazzin; Claudio Tiribelli
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

6.  Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals: potential mechanism of peripheral impairment in motor neuron diseases associated with hyperhomocysteinemia.

Authors:  Ellya Bukharaeva; Anastasia Shakirzyanova; Venera Khuzakhmetova; Guzel Sitdikova; Rashid Giniatullin
Journal:  Front Cell Neurosci       Date:  2015-10-06       Impact factor: 5.505

7.  Does Celiac Disease Influence Survival in Sepsis? A Nationwide Longitudinal Study.

Authors:  Anna Röckert Tjernberg; Jonas Bonnedahl; Jonas F Ludvigsson
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

Review 8.  B Vitamins and Fatty Acids: What Do They Share with Small Vessel Disease-Related Dementia?

Authors:  Rita Moretti; Costanza Peinkhofer
Journal:  Int J Mol Sci       Date:  2019-11-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.